<VariationArchive VariationID="1179211" VariationName="GRCh37/hg19 Xq22.3(chrX:107683053-107940795)" VariationType="copy number loss" Accession="VCV001179211" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-05-08" DateCreated="2021-07-18" MostRecentSubmission="2021-07-18">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1168595" VariationID="1179211">
      <GeneList>
        <Gene Symbol="COL4A5" FullName="collagen type IV alpha 5 chain" GeneID="1287" HGNC_ID="HGNC:2207" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>Xq22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="108439838" stop="108697545" display_start="108439838" display_stop="108697545" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="107683073" stop="107940774" display_start="107683073" display_stop="107940774" Strand="+" />
          </Location>
          <OMIM>303630</OMIM>
          <Haploinsufficiency last_evaluated="2020-09-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL4A5">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-09-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL4A5">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>GRCh37/hg19 Xq22.3(chrX:107683053-107940795)</Name>
      <VariantType>copy number loss</VariantType>
      <Location>
        <CytogeneticLocation>Xq22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" innerStart="107683053" innerStop="107940795" display_start="107683053" display_stop="107940795" variantLength="257743" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.(?_107683053)_(107940795_?)del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.(?_107683053)_(107940795_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="GRCh37/hg19 Xq22.3(chrX:107683053-107940795) AND X-linked Alport syndrome" Accession="RCV001536132" Version="3">
        <ClassifiedConditionList TraitSetID="2968">
          <ClassifiedCondition DB="MedGen" ID="C4746986">X-linked Alport syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-07-18" MostRecentSubmission="2021-07-18">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="2968" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="220" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Alport syndrome 1, X-linked recessive</ElementValue>
                <XRef ID="Alport+Syndrome/335" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alport Syndrome and Thin Basement Membrane Nephropathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">NEPHROPATHY AND DEAFNESS, X-LINKED</ElementValue>
                <XRef Type="MIM" ID="301050" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">X-linked Alport syndrome</ElementValue>
                <XRef ID="MONDO:0010520" DB="MONDO" />
                <XRef ID="88917" DB="Orphanet" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">XLAS</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">ATS1</ElementValue>
                <XRef Type="MIM" ID="301050" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATS</ElementValue>
                <XRef ID="GTR000525320" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="301050" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">COL4A5-Related Nephropathy</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16774" />
                <XRef ID="16774" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5785" />
                <XRef ID="5785" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">In Alport syndrome (AS) a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities to isolated hematuria with a non-progressive or very slowly progressive course is observed. Approximately two thirds of AS is X-linked (XLAS); approximately 15% is autosomal recessive (ARAS), and approximately 20% is autosomal dominant (ADAS). In the absence of treatment, renal disease progresses from microscopic hematuria (microhematuria) to proteinuria, progressive renal insufficiency, and end-stage renal disease (ESRD) in all males with XLAS, and in all males and females with ARAS. Progressive sensorineural hearing loss (SNHL) is usually present by late childhood or early adolescence. Ocular findings include anterior lenticonus (which is virtually pathognomonic), maculopathy (whitish or yellowish flecks or granulations in the perimacular region), corneal endothelial vesicles (posterior polymorphous dystrophy), and recurrent corneal erosion. In individuals with ADAS, ESRD is frequently delayed until later adulthood, SNHL is relatively late in onset, and ocular involvement is rare.</Attribute>
                <XRef ID="NBK1207" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301386</ID>
                <ID Source="BookShelf">NBK1207</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2002">
                <ID Source="pmc">3110944</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGentest, 2011">
                <ID Source="PubMed">22166944</ID>
              </Citation>
              <XRef ID="63" DB="Orphanet" />
              <XRef ID="88917" DB="Orphanet" />
              <XRef ID="C4746986" DB="MedGen" />
              <XRef ID="MONDO:0010520" DB="MONDO" />
              <XRef Type="MIM" ID="301050" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3448327" SubmissionDate="2021-07-09" DateLastUpdated="2021-07-18" DateCreated="2021-07-18">
        <ClinVarSubmissionID localKey=":Chr.X_107683053_107940795_copy number loss|OMIM:301050" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001752851" DateUpdated="2021-07-18" DateCreated="2021-07-18" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL4A5" />
          </GeneList>
          <VariantType>copy number loss</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="X" innerStart="107683053" innerStop="107940795" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="301050" Type="MIM" />
          </Trait>
        </TraitSet>
        <Comment>This variant has been detected in individual(s) who were sent for testing of Renasight - kidney gene panel.</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB9977930</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3448327" TraitType="Disease" MappingType="XRef" MappingValue="301050" MappingRef="OMIM">
        <MedGen CUI="C4746986" Name="X-linked Alport syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

